Anti-hepatitis Agents

Random Miscellaneous Quiz

Can you name the Anti-hepatitis Agents?

Quiz not verified by Sporcle

 plays        
How to Play
HintAnswer
SE: HA, fatigue, nausea. Potential mitochondrial toxicity (lactic acidosis & hepatic steatosis)
P-kinetics: Lipophilic (pivoxil) moiety enhances oral bioavailability.
MOA: Serine protease inhibitors. Bind to inhibit HCV non-structural protein NS3
MOA: A prodrug of adefovir (adenosine analogue). Slows suppression of HBV DNA; least seroconversion
P-kinetics:Oral bioavailability not affected by food. Emergence of resistance in long term use.
Use: HBV: Safer for pts w/ decompensated liver dz. For both adults & peds
SE: Dose-dependent hemolytic anemia. Depression, fatigue, irritability, nausea, insomnia.
P-kinetics: Synthetic (consensus). SC
Group MOA: 3 major enzymes are activated by IFN-JNK/STAT signaling pathway: (1) 2',5' oligo A synthase: produces 2'5' oligo A.
P-kinetics: Oral (TID). P450 substrates (potential rx interactions)
P-kinetics: Natural. SC or IM
Tenofovir Class
Contraindications: Hepatic decompensation, autoimmune dz, cardiac arrhythmia, pregnancy
Group MOA cont. (3) Protein kinase (activated by dsRNA): phosphorylates/inhibits eIF-2, therefore blocking PRO synthesis
IFN α-2a/2b class
Use: Improve therapeutic response in pts (>18 yo) w/ HCV genotype 1 when combined w/ IFN/ribavirin
Group MOA: Competively inhibit HBV DNA polymerase +/- incorporate into viral DNA causing chain termination. Phosphorylated to active forms intracellularly by cellular kinases.
Group P-kinetics: Pills once a day for a year or longer
Drug MOA: PEG = polyethylene glycol
Telaprevir Class
Group MOA cont. (2) Ribonuclease L (activated by 2'5' oligo A): degrades mRNA.
P-kinetics: Higher rate of complete response & less resistance vs. adefovir
SE: Anemia, neutropenia, dysgeusia, skin rash (esp. telaprevir), increased QT intervals (telaprevir)
IFN alfacon-1 class
Use: HBV treatment adults only
HintAnswer
SE: Flu-like symptoms (fever, chills, myalgias, malaise). Neurotoxicity, myelosuppression, fatigue (chronic use). Transient hepatic enzyme elevation.
P-kinetics: Clinical resistance is rare. Oral bioavailability decreased by food (taken w/ empty stomach). Renal elimination (serum concentration increased w/ altered kidney activit
PEG-IFN α-2a Class
Lamivudine (3TC, Heptovir) Class
MOA: A thymidine analog
Use: Lamivudine-resistant HBV. Adults only
IFN α-2b Class
MOA: A guanisine analog. Inhibits all 3 functions of HBV RNA-dependent DNA polymerase (base priming, reverse transcription of the -strand, synthesis of the + strand of HBV DNA.
SE: Increased pancreatitis in HIV/HBV pts. Emergence of resistance (mutations of DNA polymerase)
Use: Effective suppression of HBV DNA, normalization of ALT & reducing HBeAg. Adults only
Contraindications: Pts w/ uncorrected anemia, ESRD, preggo. Teratogenic: avoid pregnancy for > 6 mos thereafter
PEG-IFN α-2a/2b class
P-kinetics: Oral bioavailability increased with high-fat meal, decreased with antacid.
MOA: A prodrug (a guanosine nucleoside analogue). Phosphorylated by host cell enzymes; inhibits viral RNA-dependent polymerases.
Telbivudine (Tyzeka) Class
Boceprevir Class
MOA: A cytosine analogue
MOA: An adenosine analogue. Structurally similar to adefovir.
Group MOA cont: Associated with mitochondrial DNA toxicity (by inhibiting DNA polymerase gamma)
P-kinetics: Slower clearance (less frequent dosing). Dosage adjustment is needed in renal dysfunction
Use: The most potent anti-HBV agent. Adults only
Entecavir (Baraclude) Class
SE: Nephrotoxicity (at high doses). Potential mitochondrial DNA toxicity
P-kinetics: Prolonged intracellular half-life in HBV (than in HIV). Rapid oral absorption; eliminated unchanged. Used at lower doses for hepatitis than for AIDS.
Adefovir dipivoxil (Hepsera) Class

Friend Scores


  Player Best Score Plays Last Played
You You haven't played this game yet.

You Might Also Like...

Extras

Created Feb 10, 2012ReportNominate
Tags:agent